;PMID: 2351099
;source_file_1893.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..120] = [t:45..120]
;2)sentence:[e:121..175] = [t:121..175]
;3)section:[e:179..211] = [t:179..211]
;4)section:[e:215..320] = [t:215..320]
;5)sentence:[e:324..450] = [t:324..450]
;6)sentence:[e:451..600] = [t:451..600]
;7)sentence:[e:601..852] = [t:601..852]
;8)sentence:[e:853..1051] = [t:853..1051]
;9)sentence:[e:1052..1216] = [t:1052..1216]
;10)sentence:[e:1217..1307] = [t:1217..1307]
;11)sentence:[e:1308..1467] = [t:1308..1467]
;12)sentence:[e:1468..1571] = [t:1468..1571]
;13)sentence:[e:1572..1804] = [t:1572..1804]
;14)sentence:[e:1805..2020] = [t:1805..2020]
;15)section:[e:2024..2068] = [t:2024..2068]

;section 0 Span:0..39
;Endocrinology. 1990 Jun;126(6):2868-75.
(SEC
  (FRAG (NNP:[0..13] Endocrinology) (,:[13..14] .) (CD:[15..19] 1990)
        (.:[20..27] Jun;126) (-LRB-:[27..28] -LRB-) (CD:[28..29] 6)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..35] 2868)
        (HYPH:[35..36] -) (CD:[36..38] 75) (.:[38..39] .)))

;sentence 1 Span:45..120
;Expression of 25-hydroxyvitamin D3-24-hydroxylase activity in Caco-2 cells.
;[59..94]:substance:"25-hydroxyvitamin D3-24-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[45..55] Expression))
    (PP (IN:[56..58] of)
      (NP
         (NN:[59..76] 25-hydroxyvitamin) (NN:[77..94] D3-24-hydroxylase)
        (NN:[95..103] activity)))
    (PP-LOC (IN:[104..106] in)
      (NP (NN:[107..113] Caco-2) (NNS:[114..119] cells)))
    (.:[119..120] .)))

;sentence 2 Span:121..175
;An  in vitro model of intestinal vitamin D catabolism.
;[154..163]:substance:"vitamin D"
(SENT
  (NP-HLN
    (NP (DT:[121..123] An)
      (ADJP (FW:[125..127] in) (FW:[128..133] vitro))
      (NN:[134..139] model))
    (PP (IN:[140..142] of)
      (NP (JJ:[143..153] intestinal)
        (NML (NN:[154..161] vitamin) (NN:[162..163] D))
        (NN:[164..174] catabolism)))
    (.:[174..175] .)))

;section 3 Span:179..211
;Tomon M, Tenenhouse HS, Jones G.
(SEC
  (FRAG (NNP:[179..184] Tomon) (NNP:[185..187] M,) (NNP:[188..198] Tenenhouse)
        (NNP:[199..201] HS) (,:[201..202] ,) (NNP:[203..208] Jones)
        (NNP:[209..211] G.)))

;section 4 Span:215..320
;Medical Research Council Genetics Group, McGill University-Montreal
;Children's  Hospital, Quebec, Canada.
(SEC
  (FRAG (NNP:[215..222] Medical) (NNP:[223..231] Research)
        (NNP:[232..239] Council) (NNP:[240..248] Genetics)
        (NNP:[249..254] Group) (,:[254..255] ,) (NNP:[256..262] McGill)
        (NNP:[263..282] University-Montreal) (NNP:[283..291] Children)
        (POS:[291..293] 's) (NNP:[295..303] Hospital) (,:[303..304] ,)
        (NNP:[305..311] Quebec) (,:[311..312] ,) (NNP:[313..319] Canada)
        (.:[319..320] .)))

;sentence 5 Span:324..450
;The C-24 oxidation pathway plays a major role in the degradation of vitamin D
; metabolites in kidney and other target tissues.
;[392..414]:substance:"vitamin D  metabolites"
(SENT
  (S
    (NP-SBJ (DT:[324..327] The) (NN:[328..332] C-24) (NN:[333..342] oxidation)
            (NN:[343..350] pathway))
    (VP (VBZ:[351..356] plays)
      (NP (DT:[357..358] a) (JJ:[359..364] major) (NN:[365..369] role))
      (PP (IN:[370..372] in)
        (NP
          (NP (DT:[373..376] the) (NN:[377..388] degradation))
          (PP (IN:[389..391] of)
            (NP
              (NML (NN:[392..399] vitamin) (NN:[400..401] D))
              (NNS:[403..414] metabolites)))
          (PP (IN:[415..417] in)
            (NP
              (NP (NN:[418..424] kidney)
                (NML-1 (-NONE-:[424..424] *P*)))
              (CC:[425..428] and)
              (NP (JJ:[429..434] other) (NN:[435..441] target)
                (NML-1 (NNS:[442..449] tissues))))))))
    (.:[449..450] .)))

;sentence 6 Span:451..600
;The aim of the present study was  to establish an intestinal cell culture
;system to study the mechanisms  regulating the vitamin D catabolic pathway.
;[572..581]:substance:"vitamin D"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[451..454] The) (NN:[455..458] aim))
      (PP (IN:[459..461] of)
        (NP (DT:[462..465] the) (JJ:[466..473] present) (NN:[474..479] study))))
    (VP (VBD:[480..483] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[483..483] *))
        (VP (TO:[485..487] to)
          (VP (VB:[488..497] establish)
            (NP (DT:[498..500] an) (JJ:[501..511] intestinal)
              (NML (NN:[512..516] cell) (NN:[517..524] culture))
              (NN:[525..531] system))
            (S-PRP
              (NP-SBJ (-NONE-:[531..531] *))
              (VP (TO:[532..534] to)
                (VP (VB:[535..540] study)
                  (NP
                    (NP (DT:[541..544] the) (NNS:[545..555] mechanisms))
                    (VP (VBG:[557..567] regulating)
                      (NP (DT:[568..571] the)
                        (NML (NN:[572..579] vitamin) (NN:[580..581] D))
                        (JJ:[582..591] catabolic) (NN:[592..599] pathway)))))))))))
    (.:[599..600] .)))

;sentence 7 Span:601..852
;25-Hydroxyvitamin D3-24-hydroxylase  (24-hydroxylase), the first enzyme in
;the catabolic sequence, was examined in  Caco-2 cells, a human colon
;adenocarcinoma cell line which exhibits  differentiated functions of
;absorbing intestinal epithelial cells.
;[601..636]:cyp450:"25-Hydroxyvitamin D3-24-hydroxylase"
;[639..653]:cyp450:"24-hydroxylase"
;[666..672]:cyp450:"enzyme"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (NN:[601..618] 25-Hydroxyvitamin) (NN:[619..636] D3-24-hydroxylase))
        (NP (-LRB-:[638..639] -LRB-) (NN:[639..653] 24-hydroxylase)
            (-RRB-:[653..654] -RRB-)))
      (,:[654..655] ,)
      (NP
        (NP (DT:[656..659] the) (JJ:[660..665] first) (NN:[666..672] enzyme))
        (PP (IN:[673..675] in)
          (NP (DT:[676..679] the) (JJ:[680..689] catabolic)
              (NN:[690..698] sequence)))))
    (,:[698..699] ,)
    (VP (VBD:[700..703] was)
      (VP (VBN:[704..712] examined)
        (NP-2 (-NONE-:[712..712] *))
        (PP-LOC (IN:[713..715] in)
          (NP
            (NP (NN:[717..723] Caco-2) (NNS:[724..729] cells))
            (,:[729..730] ,)
            (NP
              (NP (DT:[731..732] a) (JJ:[733..738] human) (NN:[739..744] colon)
                  (NN:[745..759] adenocarcinoma) (NN:[760..764] cell)
                  (NN:[765..769] line))
              (SBAR
                (WHNP-1 (WDT:[770..775] which))
                (S
                  (NP-SBJ-1 (-NONE-:[775..775] *T*))
                  (VP (VBZ:[776..784] exhibits)
                    (NP
                      (NP (VBN:[786..800] differentiated)
                          (NNS:[801..810] functions))
                      (PP (IN:[811..813] of)
                        (S-NOM
                          (NP-SBJ (-NONE-:[813..813] *))
                          (VP (VBG:[814..823] absorbing)
                            (NP (JJ:[824..834] intestinal)
                                (JJ:[835..845] epithelial)
                                (NNS:[846..851] cells))))))))))))))
    (.:[851..852] .)))

;sentence 8 Span:853..1051
;While  untreated Caco-2 cells did not exhibit 24-hydroxylase activity,
;significant  catabolic activity was induced by prior treatment of cell
;monolayers with  1,25-dihydroxyvitamin D3(1,25-(OH)2D3).
;[899..913]:cyp450:"24-hydroxylase"
;[1012..1036]:substance:"1,25-dihydroxyvitamin D3"
;[1037..1049]:substance:"1,25-(OH)2D3"
(SENT
  (S
    (SBAR-ADV (IN:[853..858] While)
      (S
        (NP-SBJ (JJ:[860..869] untreated) (NN:[870..876] Caco-2)
                (NNS:[877..882] cells))
        (VP (VBD:[883..886] did) (RB:[887..890] not)
          (VP (VB:[891..898] exhibit)
            (NP (NN:[899..913] 24-hydroxylase) (NN:[914..922] activity))))))
    (,:[922..923] ,)
    (NP-SBJ-1 (JJ:[924..935] significant) (JJ:[937..946] catabolic)
              (NN:[947..955] activity))
    (VP (VBD:[956..959] was)
      (VP (VBN:[960..967] induced)
        (NP-1 (-NONE-:[967..967] *))
        (PP (IN:[968..970] by)
          (NP-LGS
            (NP (JJ:[971..976] prior) (NN:[977..986] treatment))
            (PP (IN:[987..989] of)
              (NP (NN:[990..994] cell) (NNS:[995..1005] monolayers)))
            (PP (IN:[1006..1010] with)
              (NP
                (NP (NN:[1012..1033] 1,25-dihydroxyvitamin) (NN:[1034..1036] D3))
                (NP (-LRB-:[1036..1037] -LRB-)
                    (NN:[1037..1049] 1,25--LRB-OH-RRB-2D3)
                    (-RRB-:[1049..1050] -RRB-))))))))
    (.:[1050..1051] .)))

;sentence 9 Span:1052..1216
;Induced 24-hydroxylase D3 (25OHD3) and  1,25-(OH)2D3 was detected 6 h after
;treatment of cells with 10(-8)M  1,25-(OH)2D3, peaked at 16 h, and decreased
;thereafter.
;[1060..1077]:cyp450:"24-hydroxylase D3"
;[1079..1085]:cyp450:"25OHD3"
;[1092..1104]:substance:"1,25-(OH)2D3"
;[1118..1119]:quantitative-value:"6"
;[1120..1121]:quantitative-units:"h"
;[1152..1158]:quantitative-value:"10(-8)"
;[1158..1159]:quantitative-units:"M"
;[1161..1173]:substance:"1,25-(OH)2D3"
;[1185..1187]:quantitative-value:"16"
;[1188..1189]:quantitative-units:"h"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP
          (ADJP-1 (VBN:[1052..1059] Induced))
           (NN:[1060..1074] 24-hydroxylase) (NN:[1075..1077] D3))
        (NP (-LRB-:[1078..1079] -LRB-) (NN:[1079..1085] 25OHD3)
            (-RRB-:[1085..1086] -RRB-)))
      (CC:[1087..1090] and)
      (NP
        (ADJP-1 (-NONE-:[1090..1090] *P*))
        (NN:[1092..1104] 1,25--LRB-OH-RRB-2D3)))
    (VP
      (VP (VBD:[1105..1108] was)
        (VP (VBN:[1109..1117] detected)
          (NP-2 (-NONE-:[1117..1117] *))
          (PP-TMP
            (NP-ADV (CD:[1118..1119] 6) (NN:[1120..1121] h))
            (IN:[1122..1127] after)
            (NP
              (NP (NN:[1128..1137] treatment))
              (PP (IN:[1138..1140] of)
                (NP (NNS:[1141..1146] cells)))
              (PP (IN:[1147..1151] with)
                (NP (CD:[1152..1158] 10-LRB--8-RRB-) (NN:[1158..1159] M)
                    (NN:[1161..1173] 1,25--LRB-OH-RRB-2D3))))))
        (,:[1173..1174] ,))
      (VP (VBD:[1175..1181] peaked)
        (PP-TMP (IN:[1182..1184] at)
          (NP (CD:[1185..1187] 16) (NN:[1188..1189] h))))
      (,:[1189..1190] ,) (CC:[1191..1194] and)
      (VP (VBD:[1195..1204] decreased)
        (ADVP (RB:[1205..1215] thereafter))))
    (.:[1215..1216] .)))

;sentence 10 Span:1217..1307
;Treatment of cells with  10(-7) M 1,25-(OH)2D3 elicited a maximal
;24-hydroxylase response.
;[1242..1248]:quantitative-value:"10(-7)"
;[1249..1250]:quantitative-units:"M"
;[1251..1263]:quantitative-value:"1,25-(OH)2D3"
;[1283..1297]:cyp450:"24-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1217..1226] Treatment))
      (PP (IN:[1227..1229] of)
        (NP (NNS:[1230..1235] cells)))
      (PP (IN:[1236..1240] with)
        (NP
          (NML (CD:[1242..1248] 10-LRB--7-RRB-) (NN:[1249..1250] M))
          (NN:[1251..1263] 1,25--LRB-OH-RRB-2D3))))
    (VP (VBD:[1264..1272] elicited)
      (NP (DT:[1273..1274] a) (JJ:[1275..1282] maximal)
          (NN:[1283..1297] 24-hydroxylase) (NN:[1298..1306] response)))
    (.:[1306..1307] .)))

;sentence 11 Span:1308..1467
;Comparable  time courses of induction by 1,25-(OH)2D3 and 1,25-(OH)2D3-dose
;response curves  were observed in cultured human skin fibroblasts and Caco-2
;cells.
;[1349..1361]:substance:"1,25-(OH)2D3"
;[1366..1378]:substance:"1,25-(OH)2D3"
(SENT
  (S
    (NP-SBJ-4
      (NP (JJ:[1308..1318] Comparable) (NN:[1320..1324] time)
          (NNS:[1325..1332] courses))
      (PP (IN:[1333..1335] of)
        (NP
          (NP (NN:[1336..1345] induction))
          (PP (IN:[1346..1348] by)
            (NP
              (NP
                (NML (NN:[1349..1361] 1,25--LRB-OH-RRB-2D3)
                  (NML-3 (-NONE-:[1361..1361] *P*)))
                (NML-5 (-NONE-:[1361..1361] *P*)))
              (CC:[1362..1365] and)
              (NP
                (NML (NN:[1366..1378] 1,25--LRB-OH-RRB-2D3)
                  (NML-3 (HYPH:[1378..1379] -) (NN:[1379..1383] dose)))
                (NML-5 (NN:[1384..1392] response) (NNS:[1393..1399] curves))))))))
    (VP (VBD:[1401..1405] were)
      (VP (VBN:[1406..1414] observed)
        (NP-4 (-NONE-:[1414..1414] *))
        (PP-LOC (IN:[1415..1417] in)
          (NP
            (NP
              (ADJP-1 (VBN:[1418..1426] cultured))
              (ADJP-2 (JJ:[1427..1432] human))
              (NN:[1433..1437] skin) (NNS:[1438..1449] fibroblasts))
            (CC:[1450..1453] and)
            (NP
              (ADJP-1 (-NONE-:[1453..1453] *P*))
              (ADJP-2 (-NONE-:[1453..1453] *P*))
              (NN:[1454..1460] Caco-2) (NNS:[1461..1466] cells))))))
    (.:[1466..1467] .)))

;sentence 12 Span:1468..1571
;25OHD3 was  not as good an inducer of the vitamin D catabolic pathway in
;Caco-2 cells as  1,25-(OH)2D3.
;[1468..1474]:cyp450:"25OHD3"
;[1510..1519]:substance:"vitamin D"
;[1558..1570]:substance:"1,25-(OH)2D3"
(SENT
  (S
    (NP-SBJ (NN:[1468..1474] 25OHD3))
    (VP (VBD:[1475..1478] was) (RB:[1480..1483] not)
      (NP-PRD
        (NP
          (ADJP
            (ADJP (RB:[1484..1486] as) (JJ:[1487..1491] good))
            (PP-1 (-NONE-:[1491..1491] *ICH*)))
          (DT:[1492..1494] an) (NN:[1495..1502] inducer))
        (PP (IN:[1503..1505] of)
          (NP (DT:[1506..1509] the)
            (NML (NN:[1510..1517] vitamin) (NN:[1518..1519] D))
            (JJ:[1520..1529] catabolic) (NN:[1530..1537] pathway))))
      (PP-LOC (IN:[1538..1540] in)
        (NP (NN:[1541..1547] Caco-2) (NNS:[1548..1553] cells)))
      (PP-1 (IN:[1554..1556] as)
        (NP (NN:[1558..1570] 1,25--LRB-OH-RRB-2D3))))
    (.:[1570..1571] .)))

;sentence 13 Span:1572..1804
;Induction of 24-hydroxylase activity by 1,25-(OH)2D3 was inhibited  by
;pretreatment of Caco-2 cells with either actinomycin D, alpha-amanitin, or 
;cycloheximide suggesting that mRNA and protein synthesis are required for 
;induction.
;[1585..1599]:cyp450:"24-hydroxylase"
;[1612..1624]:substance:"1,25-(OH)2D3"
;[1684..1697]:substance:"actinomycin D"
;[1699..1713]:substance:"alpha-amanitin"
;[1719..1732]:substance:"cycloheximide"
;[1749..1753]:substance:"mRNA"
;[1758..1765]:substance:"protein"
(SENT
  (S
    (NP-SBJ-3
      (NP (NN:[1572..1581] Induction))
      (PP (IN:[1582..1584] of)
        (NP (NN:[1585..1599] 24-hydroxylase) (NN:[1600..1608] activity)))
      (PP (IN:[1609..1611] by)
        (NP (NN:[1612..1624] 1,25--LRB-OH-RRB-2D3))))
    (VP (VBD:[1625..1628] was)
      (VP (VBN:[1629..1638] inhibited)
        (NP-3 (-NONE-:[1638..1638] *))
        (PP (IN:[1640..1642] by)
          (NP-LGS
            (NP (NN:[1643..1655] pretreatment))
            (PP (IN:[1656..1658] of)
              (NP (NN:[1659..1665] Caco-2) (NNS:[1666..1671] cells)))
            (PP (IN:[1672..1676] with)
              (NP (CC:[1677..1683] either)
                (NP (NN:[1684..1695] actinomycin) (NN:[1696..1697] D))
                (,:[1697..1698] ,)
                (NP (NN:[1699..1713] alpha-amanitin))
                (,:[1713..1714] ,) (CC:[1715..1717] or)
                (NP (NN:[1719..1732] cycloheximide))))))
        (S-MNR
          (NP-SBJ (-NONE-:[1732..1732] *))
          (VP (VBG:[1733..1743] suggesting)
            (SBAR (IN:[1744..1748] that)
              (S
                (NP-SBJ-2
                  (NP (NN:[1749..1753] mRNA)
                    (NML-1 (-NONE-:[1753..1753] *P*)))
                  (CC:[1754..1757] and)
                  (NP (NN:[1758..1765] protein)
                    (NML-1 (NN:[1766..1775] synthesis))))
                (VP (VBP:[1776..1779] are)
                  (VP (VBN:[1780..1788] required)
                    (NP-2 (-NONE-:[1788..1788] *))
                    (PP (IN:[1789..1792] for)
                      (NP (NN:[1794..1803] induction)))))))))))
    (.:[1803..1804] .)))

;sentence 14 Span:1805..2020
;The present study demonstrates that 1,25-(OH)2D3-treated Caco-2 cells 
;express the vitamin D catabolic pathway and, therefore, constitute a useful
;in  vitro model to study the mechanism of induction by 1,25-(OH)2D3.
;[1841..1853]:substance:"1,25-(OH)2D3"
;[1888..1897]:substance:"vitamin D"
;[2007..2019]:substance:"1,25-(OH)2D3"
(SENT
  (S
    (NP-SBJ (DT:[1805..1808] The) (JJ:[1809..1816] present)
            (NN:[1817..1822] study))
    (VP (VBZ:[1823..1835] demonstrates)
      (SBAR (IN:[1836..1840] that)
        (S
          (NP-SBJ
            (ADJP (NN:[1841..1853] 1,25--LRB-OH-RRB-2D3) (HYPH:[1853..1854] -)
                  (VBN:[1854..1861] treated))
            (NN:[1862..1868] Caco-2) (NNS:[1869..1874] cells))
          (VP
            (VP (VBP:[1876..1883] express)
              (NP (DT:[1884..1887] the)
                (NML (NN:[1888..1895] vitamin) (NN:[1896..1897] D))
                (JJ:[1898..1907] catabolic) (NN:[1908..1915] pathway)))
            (CC:[1916..1919] and) (,:[1919..1920] ,)
            (VP
              (ADVP (RB:[1921..1930] therefore))
              (,:[1930..1931] ,) (VBP:[1932..1942] constitute)
              (NP (DT:[1943..1944] a) (JJ:[1945..1951] useful)
                (ADJP (FW:[1952..1954] in) (FW:[1956..1961] vitro))
                (NN:[1962..1967] model))
              (S-ADV
                (NP-SBJ (-NONE-:[1967..1967] *))
                (VP (TO:[1968..1970] to)
                  (VP (VB:[1971..1976] study)
                    (NP
                      (NP (DT:[1977..1980] the) (NN:[1981..1990] mechanism))
                      (PP (IN:[1991..1993] of)
                        (NP
                          (NP (NN:[1994..2003] induction))
                          (PP (IN:[2004..2006] by)
                            (NP (NN:[2007..2019] 1,25--LRB-OH-RRB-2D3))))))))))))))
    (.:[2019..2020] .)))

;section 15 Span:2024..2068
;PMID: 2351099 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2024..2028] PMID) (::[2028..2029] :) (CD:[2030..2037] 2351099)
        (NN:[2038..2039] -LSB-) (NNP:[2039..2045] PubMed) (::[2046..2047] -)
        (NN:[2048..2055] indexed) (IN:[2056..2059] for)
        (NNP:[2060..2068] MEDLINE-RSB-)))
